Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma

References

• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.
   PubMed Web of Science ®Google Scholar
• Oranger A, Carbone C, Izzo M, et al. Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol 2013;2013:289458.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655–1664.
   PubMed Web of Science ®Google Scholar
• Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411–425.
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860–1867.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376:1989–1999.
   PubMed Web of Science ®Google Scholar
• Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013;31:2347–2357.
   PubMed Web of Science ®Google Scholar
• Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci 2007;1117:209–257.
   PubMed Web of Science ®Google Scholar
• Corso A, Ferretti E, Lazzarino M. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment. Hematology 2005;10:215–224.
   PubMed Web of Science ®Google Scholar
• Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482–492.
   PubMed Web of Science ®Google Scholar
• Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010;126:239–246.
   PubMed Web of Science ®Google Scholar
• Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997;98:665–672.
   PubMed Web of Science ®Google Scholar
• Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013;24:398–405.
   PubMed Web of Science ®Google Scholar
• Coleman R, Gnant M, Morgan G, et al. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012;104:1059–1067.
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679–691.
   PubMed Web of Science ®Google Scholar
• Lipton A. Zoledronic acid: multiplicity of use across the cancer continuum. Expert Rev Anticancer Ther 2011;11:999–1012.
   PubMed Web of Science ®Google Scholar
• Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745–751.
   PubMed Web of Science ®Google Scholar
• Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002;45:3721–3738.
   Google Scholar
• Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012;(5):CD003188.
   Google Scholar
• Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075–1079; discussion 1081–1090.
   PubMed Web of Science ®Google Scholar
• Velde NV, Wu EQ, Guo A, et al. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Prostate Cancer Prostatic Dis 2011;14:79–84.
   PubMed Web of Science ®Google Scholar
• Krupski TL, Foley KA, Baser O, et al. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007;178:1423–1428.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:257–281.
   Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70: 41–55.
   Web of Science ®Google Scholar
• Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 2004; 75:45–49.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98: 1735–1744.
   PubMed Web of Science ®Google Scholar
• Sohn MW, Arnold N, Maynard C, et al. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr 2006;4:2.
   PubMedGoogle Scholar
• McCarthy PL Jr, Hahn T, Hassebroek A, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013;19:1116–1123.
   PubMed Web of Science ®Google Scholar
• ANDA (Generic) Drug Approvals. 2013. Available from: wwwfdagov/drugs/developmentapprovalprocess/howdrugsare developedandapproved/drugandbiologicapprovalreports/anda genericdrugapprovals/ucm349492htm
   Google Scholar
• Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. Oncologist 2004;9:319–329.
   PubMed Web of Science ®Google Scholar